OSEBX1,423.56+0.84%
EQNR284.60+4.20%
DNB198.35-1.15%
MOWI172.80+0.45%
Brent$71.24-0.32%
EUR/USD1.0824-0.14%
DXY104.18+0.08%
INDICATIVE · SAMPLE DATA
ESLX57

Essilorluxottica SA

Medical Equipment, Supplies & DistributionVerified

Capital Structure and Liquidity Essilorluxottica has a basic and diluted share count of 463,190,305 shares outstanding, indicating no immediate dilution pressure from share-based compensation or convertible instruments. However, liquidity risk could not be assessed due to missing balance-sheet inputs and no going-concern language in source documents. ### Profitability and Returns The company's profitability and return metrics are not available in the current valuation snapshot, precluding a direct comparison to industry_config preferred metrics or cohort medians. Analysts have assigned a mean price target of 300.90 EUR and a median of 310.00 EUR, with a mean recommendation of 1.76, suggesting a generally positive outlook. ### Segments and Geographic Exposure No detailed segment or geographic revenue breakdown is available in the current dataset, limiting the ability to assess revenue concentration or exposure to specific markets. ### Growth Trajectory The company's growth trajectory is not quantified in the current dataset, but the analyst price targets and recommendation scores suggest a generally optimistic view of future performance. ### Risk Factors The primary risk factor is the inability to assess liquidity risk due to missing balance-sheet data. Dilution risk is currently low, with no evidence of dilutive events in the near term. ### Recent Events No recent filings or transcripts are available in the current dataset to inform on recent company developments or strategic shifts.

30-day price · EL+0.43 (+0.5%)
Low$66.22High$91.06Close$80.17As of18 May, 00:00 UTC
Profile
CompanyEssilorluxottica SA
TickerESLX.PA
SectorHealthcare
BusinessHealthcare Services & Equipment
Industry groupHealthcare Services & Equipment
IndustryMedical Equipment, Supplies & Distribution
AI analysis

Business. Essilorluxottica SA designs, produces, and distributes ophthalmic lenses and eyewear, including prescription lenses, sunglasses, and contact lenses, primarily through its retail and wholesale channels.

Classification. Essilorluxottica is classified in the industry "Medical Equipment, Supplies & Distribution" under the Healthcare Services & Equipment business sector, with a confidence level of 0.92.

### Capital Structure and Liquidity Essilorluxottica has a basic and diluted share count of 463,190,305 shares outstanding, indicating no immediate dilution pressure from share-based compensation or convertible instruments. However, liquidity risk could not be assessed due to missing balance-sheet inputs and no going-concern language in source documents. ### Profitability and Returns The company's profitability and return metrics are not available in the current valuation snapshot, precluding a direct comparison to industry_config preferred metrics or cohort medians. Analysts have assigned a mean price target of 300.90 EUR and a median of 310.00 EUR, with a mean recommendation of 1.76, suggesting a generally positive outlook. ### Segments and Geographic Exposure No detailed segment or geographic revenue breakdown is available in the current dataset, limiting the ability to assess revenue concentration or exposure to specific markets. ### Growth Trajectory The company's growth trajectory is not quantified in the current dataset, but the analyst price targets and recommendation scores suggest a generally optimistic view of future performance. ### Risk Factors The primary risk factor is the inability to assess liquidity risk due to missing balance-sheet data. Dilution risk is currently low, with no evidence of dilutive events in the near term. ### Recent Events No recent filings or transcripts are available in the current dataset to inform on recent company developments or strategic shifts.
Key takeaways
  • Essilorluxottica is a leading player in the medical equipment and supplies industry, with a strong analyst consensus on its future performance.
  • The company has no immediate dilution risk, as basic and diluted share counts are equal.
  • Analysts have assigned a mean price target of 300.90 EUR and a median of 310.00 EUR, indicating a generally positive outlook.
  • Liquidity risk could not be assessed due to missing balance-sheet data, which may limit the ability to evaluate financial stability.
  • No recent filings or transcripts are available to provide insight into recent company developments.
  • --
  • ## RATIONALES
  • ```json
Financial snapshot
PeriodHA-latest
CurrencyEUR
Revenue
Gross profit
Operating income
Net income
R&D
SG&A
D&A
SBC
Operating cash flow
CapEx
Free cash flow
Total assets
Total liabilities
Total equity
Cash & equivalents
Long-term debt
Annual history (last 5)
PeriodRevenueOp IncomeNet IncomeFCF
FY-4$19.82B$2.31B$1.45B$2.82B
FY-3$24.49B$3.16B$2.15B$3.18B
FY-2$25.39B$3.18B$2.29B$3.35B
FY-1$26.51B$3.45B$2.36B$2.90B
FY0$28.49B$3.38B$2.31B$3.46B
PeriodGross %Op %Net %FCF %
FY-4
FY-3
FY-2
FY-1
FY0
PeriodAssetsEquityCashDebt
FY-4$59.41B$35.06B$1.71B
FY-3$60.56B$37.45B$204.0M
FY-2$60.52B$38.24B$895.0M
FY-1$64.28B$40.38B$375.0M
FY0$63.90B$38.89B$385.0M
PeriodOCFCapExFCFSBC
FY-4$4.54B-$1.03B$2.82B
FY-3$4.78B-$1.57B$3.18B
FY-2$4.86B-$1.53B$3.35B
FY-1$4.87B-$1.52B$2.90B
FY0$5.29B-$1.52B$3.46B
Quarterly history (last 4)
PeriodRevenueOp IncomeNet IncomeFCF
FQ-7
FQ-6$6.44B
FQ-5
FQ-4$6.85B
FQ-3
FQ-2$6.87B
FQ-1
FQ0$7.13B
PeriodGross %Op %Net %FCF %
FQ-7
FQ-6
FQ-5
FQ-4
FQ-3
FQ-2
FQ-1
FQ0
PeriodAssetsEquityCashDebt
FQ-7
FQ-6
FQ-5
FQ-4
FQ-3
FQ-2
FQ-1
FQ0
PeriodOCFCapExFCFSBC
FQ-7
FQ-6
FQ-5
FQ-4
FQ-3
FQ-2
FQ-1
FQ0
Valuation
Market price
Market cap
Enterprise value
P/E
Reported non-GAAP P/E
EV/Revenue
EV/Op income
EV/OCF
P/B
P/Tangible book
Tangible book
Net cash
Current ratio
Debt/Equity
ROA
ROE
Cash conversion
CapEx/Revenue
SBC/Revenue
Asset intensity
Dilution ratio0.0%
Risk assessment
Dilution riskLow
Liquidity riskUnknown
  • Liquidity risk could not be assessed (no balance-sheet inputs and no going-concern language in source documents).
Industry benchmarks
Activity: Healthcare Services & Equipment · cohort 369 companies
MetricESLXActivity
Op margin3.9% medp25 -31.3% · p75 14.4%
Net margin2.4% medp25 -30.5% · p75 11.1%
Gross margin46.7% medp25 28.2% · p75 63.1%
R&D / revenue6.9% medp25 6.7% · p75 7.1%
CapEx / revenue-4.8% medp25 -11.6% · p75 -2.4%
Debt / equity17.9% medp25 2.7% · p75 52.2%
Observations
IR observations
Mean price target300.90 EUR
Median price target310.00 EUR
High price target361.00 EUR
Low price target185.00 EUR
Mean recommendation1.76 (1=strong buy, 5=strong sell)
Strong-buy count9.00
Buy count14.00
Hold count1.00
Sell count1.00
Strong-sell count0.00
Mean EPS estimate7.34 EUR
Last actual EPS6.83 EUR
Source data
Underlying data the analysis-pipeline pulls and audits. Fetch timestamps + content hashes show when each source was last refreshed.
Company fundamentalsperiod FQ-7 · history via verified-market-data
no public URL
2026-05-01 03:24 UTC#5560c808
Source: analysis-pipeline (hybrid)Generated: 2026-05-27 21:42 UTCJob: 1a6319a4